Parkinsons Disease With Dementia
10
3
3
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
10%
1 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (10)
A Study to Evaluate Temporary Blood Brain Barrier Disruption in Patients With Parkinson's Disease Dementia
Multidisciplinary Study of Novel NMDA Modulation for Neurodegenerative Disorder
OCT-Angiography and Adaptive Optics in Patients With Memory Impairment
A Pilot Study to Explore the Role of Gut Flora in Parkinson's Disease
ENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing
Neuropsychological Profiles and Musical Engagement in Parkinson's and Alzheimer's Disease
ANAVEX2-73 Study in Parkinson's Disease Dementia
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease
The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease